InvestSMART

Cogstate Limited (ASX:CGS)

ALERT: Price-sensitive ASX Announcement for CGS
Current share price for CGS : $2.880 0.7 (32.11%)+
Announcement
Release
19 Feb 2026 8:10AM
Price at Release
$2.180
Full Release
download
Summary
Cogstate Limited reported its financial performance for the half-year ended 31 December 2025, showcasing a net profit before tax of $5.34 million, a slight increase from the previous year. The company, operating in the digital brain health and clinical trial solutions sectors, achieved a 12% increase in operating revenue, driven largely by a 13% rise in Clinical Trials revenue. The firm has continued to focus on expanding its capabilities in CNS research, leveraging key partnerships and technological innovations. Healthcare revenue, however, remained relatively stable with a slight decrease. The Directors' declaration confirmed the financial statements' compliance with standards, and no significant subsequent events were reported.
Key Points
  • Net profit before tax for 1H26 was $5,341,147.
  • Operating revenue increased by 12% to $26.9 million.
  • Clinical Trials revenue rose by 13% to $25.7 million.
  • Healthcare segment revenue was consistent with a slight decrease.
  • Share buy-back was conducted, with 180,043 shares purchased.
  • Directors confirmed compliance with financial reporting standards.
  • No significant subsequent events affecting operations were reported.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.